85%Confidence
0Views
FDASource
2026-03-05Date
Summary
Estradiol product contamination expands Asteria Health's quality issues to hormone replacement therapies, affecting a broader patient population. This could accelerate regulatory action against the company and create market opportunities for competitors.
Actionable: Research competing hormone therapy providers that may benefit from Asteria Health's regulatory problems.
AI Confidence: 85%
Data Points
firmF.H. INVESTMENTS, Inc. (dba Asteria Health)
classificationClass II
statusOngoing
distributionNationwide in the USA
productESTRADIOL, 25 mg, 1 Sterile Pellet, Asteria Health 432 Industrial Ln, Birmingham, AL 35211, NDC: 79559-3025-32.
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now